Denise Galloway and Gerald Smith named AAAS Fellows

December 18, 2008

SEATTLE - Fred Hutchinson Cancer Research Center scientists Denise Galloway, Ph.D., a microbiologist, and Gerald Smith, Ph.D., a geneticist and microbiologist, have been awarded the distinction of AAAS Fellow. Election as a Fellow is an honor bestowed upon members of the American Association for the Advancement of Science, or AAAS, by their peers.

Galloway, a member of the Hutchinson Center's Human Biology and Public Health Sciences divisions, is being honored, according to the AAAS, "for distinguished contributions to the field of virology, particularly for the elucidation of mechanisms by which human papillomaviruses cause anogenital malignancies." Galloway studies the role of HPVs in cancer development. She and her colleagues firmly established that nearly all cervical cancers - a leading cause of cancer deaths in women worldwide - and the majority of other anogenital cancers are caused by HPVs. Breakthrough studies by her lab and others laid the groundwork for Gardasil®, a vaccine that protects against the two most common cancer-causing HPVs. Galloway is also a research professor of microbiology at the University of Washington School of Medicine.

Smith, a member of the Center's Basic Sciences Division, is being honored "for distinguished contributions to our understanding of the genetics and enzymology of homologous recombination, DNA break repair and meiosis." Smith studies the molecular mechanisms of genetic recombination to better understand diseases such as cancer and, possibly, ways to predict or prevent them. For example, his laboratory studies the genetics and enzymology of DNA-break repair, or recombination, proteins in Helicobacter pylori, a bacterium that causes stomach cancers and ulcers. Studies of these enzymes could lead to the development of new, more-effective drugs to combat many bacterial infections. Smith's lab also studies recombination during meiosis, the formation of sex cells. Mistakes in recombination during meiosis can lead to chromosome aberrancies, such as inheritance of an extra chromosome, which is the cause of Down syndrome. Smith is also an affiliate professor of genome sciences and pathology at the UW School of Medicine.

Galloway and Smith are among 486 AAAS Fellows selected this year for their "scientifically or socially distinguished efforts to advance science or its applications." For their contributions they will be presented with an official certificate and gold rosette pin Feb. 14 at the Fellows Forum during the 2009 AAAS Annual Meeting in Chicago.
-end-
The AAAS is the world's largest general scientific society and publisher of the journal Science. The organization was founded in 1848 and the tradition of electing AAAS Fellows began in 1874.At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Hutchinson Center researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society and publisher of the journal Science (www.sciencemag.org). AAAS was founded in 1848, and includes some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy; international programs; science education; and more. For the latest research news, log onto EurekAlert!, www.eurekalert.org, the premier science-news Web site, a service of AAAS.

Fred Hutchinson Cancer Research Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.